Canoso R T, Romero J A, Yunis E J
J Neuroimmunol. 1986 Sep;12(3):247-52. doi: 10.1016/s0165-5728(86)80008-x.
The presence and severity of tardive dyskinesia were determined in 66 patients with chronic psychiatric disorders treated with chlorpromazine. The patients were classified according to the presence of antinuclear antibodies, the lupus anticoagulant, and the HLA antigen Bw44. The severity of orofacial dyskinesia was estimated using the Rockland Research Institute Scale. Patients with autoantibodies and the Bw44 antigen had higher tardive dyskinesia scores than those with AAB without the Bw44 antigen and also patients without autoantibodies regardless of their HLA phenotype (P less than 0.01). These studies suggest that the presence of autoantibodies in association with the HLA Bw44 antigen is related to, and can be a predictor of, neurological complications of long-term chlorpromazine therapy.
对66例接受氯丙嗪治疗的慢性精神疾病患者的迟发性运动障碍的存在情况及严重程度进行了测定。根据抗核抗体、狼疮抗凝物及HLA抗原Bw44的存在情况对患者进行分类。使用罗克兰研究所量表评估口面部运动障碍的严重程度。伴有自身抗体和Bw44抗原的患者的迟发性运动障碍评分高于不伴有Bw44抗原的自身抗体阳性患者以及无论HLA表型如何的无自身抗体患者（P<0.01）。这些研究表明，自身抗体与HLA Bw44抗原同时存在与长期氯丙嗪治疗的神经并发症相关，且可作为其预测指标。
